A randomized controlled clinical trial (registration number NCT00760513) evaluating the effect of omega-3 on NAFLD treatment revealed that in spite of TM6SF2 risk variant carriers, those harboring PNPLA3 148M were less responsive regarding the reduction in hepatic fat content. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.